TORONTO (AP) – Canada on Monday stopped using the Oxford-AstraZeneca coronavirus vaccine for people under the age of 55 due to concerns they may have rare blood clots.
The National Immunization Advisory Committee has called for a moratorium on security concerns, with Canada’s health-controlling states announcing the moratorium on Monday.
“There is serious uncertainty about the benefits of AstraZeneca Covid-19 vaccines for adults over the age of 55, given the potential risks,” said Dr. Shelley Dix, vice chair of the National Advisory Committee on Immunization.
Dix noted that the updated proposals come amid new data from Europe, which suggests that the risk of blood clots may now reach one in 100,000, which is much higher than the previously believed million risk.
He said the majority of patients in Europe who developed a rare thrombus after being vaccinated with AstraZeneca were women under the age of 55, with a thrombosis rate of up to 40%.
Dr. oss oss Reimer of the Manitoba Vaccine Implementation Committee said that despite the conclusion that there was no risk of developing AstraZeneca-related blood clots in Europe, there was a rare but very serious side effect in Europe.
Reimer says the rare type of blood clot usually occurs within four և 20 days of receiving the shot, և the symptoms may reflect a stroke or heart attack.
“Although we still believe that the benefits of all ages outweigh the risks that I am probably not comfortable with. “I want to see more data coming out of Europe, so I know exactly what this risk-benefit analysis is,” Reimer said.
The AstraZeneca staff, authorized in more than 70 countries, is a cornerstone of a UN-supported program known as COVAX, which aims to deliver COVID-19 vaccines to poorer countries. It has also become a tool in European countries’ efforts to promote the slow spread of vaccines. This is particularly troubling for the suspects in the shooting.
“This vaccine has had all the ups and downs. “It’s like a roll,” said Dr. Caroline Kwach-Tanhi, chair of the National Advisory Committee on Immunization, when asked if the latest news would lead to further hesitation about vaccines.
Health Canada said it had not received any reports of blood clots in Canada, and Dr. Supria Sharma, the department’s chief medical adviser, said he still believed the benefits of the vaccine outweighed the risks.
Last week, the department changed the vaccine label to warn of the rare danger of blood clots.
Only people 60 and older have received AstraZeneca in Ontario, Canada’s largest state.
“We have no concerns with those who have received it yet,” said Dr. David Williams, Ontario’s chief medical officer.
Mark Mendelssohn, a 63-year-old Toronto-based man who underwent heart surgery, said he had no regrets about receiving his first dose of AstraZeneca two weeks ago and that he would receive a second.
“Get what you can,” Mendelssohn said. “I have not had any bad effects from AstraZeneca at all. I’m better off than those who have no vaccine at all. If you are a bettor, you take those odds any day of the week. “I’m pretty ready to roll the dice.”
A number of European countries that have stopped using the vaccine due to the fact that it can cause blood clots, the EU drug regulator has declared that the vaccine is safe, have resumed administration.
The vaccine is widely used in Britain, across the European continent and in other countries, but its spread has been alarmed by reports of ineffective studies, and more recently by fears of blockages that some countries have temporarily stopped vaccinating.
Canada is expected to receive 1.5 million doses of AstraZeneca from the United States this week.
“In general, the messages were harsh. I’m afraid it’s a toast. That should not be the case, “said Dr. Andrew Morris, Professor of Infectious Diseases at the University of Toronto and Medical Director of the Antimicrobial Economics Program at the University of Sinai Health Network.
Morris believes that those at high risk for COVID-19 miscarriage և over the age of 55 should get AstraZeneca if other vaccines are not available to them, especially in the third wave of coronavirus infections.
Canadian regulators have approved the Pfizer, Moderna, AstraZeneca և Johnson & Johnson vaccines. Canada has placed bigger bets on Pfizer և Moderna, ordering up to միլիոն 76 million for Pfizer և up to միլիոն 44 million for Moderna and up to միլիոն 20 million for AstraZeneca. It is not known when Canada will receive its first shipment from Johnson & Johnson.
Canada has lagged behind in vaccinating its population because it does not have the capacity to produce the vaccine and has had to rely on global supply chain rescue personnel, like many other countries.
With no domestic supply, the government of Prime Minister Justin Trudeau bet on seven different vaccines produced elsewhere and secured pre-purchase contracts. That’s enough to get 10 doses for every 38 million people in Canada. Although it has proven difficult to obtain them, deliveries have increased this month. Canada expects to have more than 36.5 million doses by July, with officials hoping to get at least one dose for adults who want one by the end of June.
The National Immunization Advisory Committee had previously recommended a four-month delay in dosing after data from the UK and Quebec showed that the level of protection was better from the first shot. Such a delay was set by Great Britain.